This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation (MAGIC-AF)

This study has been completed.
Sponsor:
Collaborator:
St. Jude Medical
Information provided by (Responsible Party):
Vivek Reddy, Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier:
NCT01014741
First received: November 16, 2009
Last updated: April 17, 2017
Last verified: April 2017
November 16, 2009
April 17, 2017
October 2009
January 2015   (Final data collection date for primary outcome measure)
1 Year Freedom From AF / AT [ Time Frame: one year ]
Freedom from atrial arrhythmia after repeat procedures with or without drugs
1 Year Freedom From AF / AT [ Time Frame: one year ]
Complete list of historical versions of study NCT01014741 on ClinicalTrials.gov Archive Site
  • Procedure Time [ Time Frame: at time of the procedure ]
    Overall procedure duration
  • AF Termination [ Time Frame: at time of the procedure ]
    AF termination with complex fractionated atrial electrograms (CFAE) ablation
  • Radiofrequency Ablation Time [ Time Frame: at time of the procedure ]
  • Procedure Time [ Time Frame: at time of the procedure ]
  • Rate of acute intra-procedural termination of AF [ Time Frame: at time of the procedure ]
  • Radiofrequency Ablation Time [ Time Frame: at time of the procedure ]
Not Provided
Not Provided
 
Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation
Modified Stepwise Ablation Guided by Low Dose Ibutilide in Chronic Atrial Fibrillation
Procedures for ablation of persistent or long lasting atrial fibrillation are frequently long and require extensive ablation. Some electrophysiologists administer the drug ibutilide during these procedures to help organize the fibrillatory activity of the left atrium with the hope that this may shorten the length of the procedure and duration of ablation needed. Currently there is no standardized approach of administering the drug ibutilide during these procedures, thus the investigators cannot be certain that administering this drug does in fact facilitate the procedure. The aim of the MAGIC-AF Trial is to see if administering a standard dose of the drug ibutilide at a standard time in the procedure can allow for a reduction in the ablation procedure time. The investigators hypothesize that administering ibutilide during these procedures will result in a reduction in the procedure and ablation time required.
Definition: Patients with persistent atrial fibrillation will be enrolled in this trial. All patients will be required to be in atrial fibrillation on the day of the procedure. Standard pulmonary vein (PV) isolation will be performed. Patients will be enrolled in the trial if they remain in atrial fibrillation after bi-directional block is obtained in the left and right sided PVs. At this point, patients will be randomized to receive 0.25mg of IV ibutilide or a placebo (normal saline). Patients will then undergo additional ablation with areas of complex fractionate electrograms (CFE) being targeted. The duration of additional CFE ablation and use of additional non-PV ablation (i.e. placement of linear lesions) will be left to the discretion of the operator. Patients will be followed for 1 year. The primary outcome assessed will be freedom from AF at 1 year.
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Persistent Atrial Fibrillation
  • Drug: Ibutilide
    0.25mg IV ibutilide after PV isolation prior to CFE ablation
  • Drug: Placebo
    Placebo after PV isolation prior to CFE ablation.
  • Experimental: Ibutilide arm
    Intervention: Drug: Ibutilide
  • Placebo Comparator: Placebo arm
    Intervention: Drug: Placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
January 2015
January 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males and females will be enrolled in the study.
  • Age >18
  • Referred for a first ever ablation procedure for symptomatic persistent/permanent AF (only prior ablation of right-sided typical flutter is permitted)
  • All patients must understand the requirements of the study and be willing to comply with the post study follow-up requirements.
  • Patients must be in atrial fibrillation on the day of the procedure

Exclusion Criteria:

  • Any reversible cause of AF (post-surgery, thyroid disorder, etc.)
  • Patients with a myocardial infarction or unstable angina in the previous 2 months.
  • Patients with a history of rheumatic heart disease
  • Patients with congenital heart disease
  • Patients with a history of hypertrophic cardiomyopathy
  • Patients with LV ejection fraction < 35%
  • Class IV congestive heart failure
  • Patients who have experienced any cerebral ischemic event, including any TIA in the preceding 1 month.
  • Women who are known to be pregnant or have had a positive β-HCG test 7 days prior to procedure.
  • Patients with any other significant uncontrolled or unstable medical condition (including uncontrolled clinically significant coagulation disorders).
  • Patients whose life expectancy is less than one year.
  • History of malignant ventricular arrhythmias or long QT interval (>500msec)
  • Prior left-sided cardiac ablation procedure (catheter based or surgical)
  • Mental impairment precluding the patient from providing informed consent or completing the appropriate follow up
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada,   Korea, Republic of,   United States
France,   Germany
 
NCT01014741
GCO 09-0906
Yes
Not Provided
Plan to Share IPD: No
Vivek Reddy, Icahn School of Medicine at Mount Sinai
Vivek Reddy
St. Jude Medical
Principal Investigator: Vivek Y Reddy, MD Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP